Cargando…
Médicaments biosimilaires : enjeux réglementaires et impacts médicoéconomiques()
The concept of biosimilar medicine was launched by 2001 and 2004 European Directives. First European marketing authorizations were delivered in 2006. They are “copies” of biologically manufactured medicines, mostly proteins. Taking into account the intrinsic variability related to the biological man...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374147/ https://www.ncbi.nlm.nih.gov/pubmed/32836292 http://dx.doi.org/10.1016/j.banm.2020.07.050 |